TAPI-0

• Description :

  TAPI-0 is a TACE (TNF-α converting enzyme; ADAM17) inhibitor with an IC50 of 100 nM. TAPI-0 is a MMP inhibitor and also attenuates TNF-α processing[1][2].

• UNSPSC :

  12352209

• Hazard Statement :

  H301

• Target :

  Bacterial; MMP; TNF Receptor

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Apoptosis; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Infection

• Assay Protocol :

  https://www.medchemexpress.com/tapi-0.html

• Purity :

  98.98

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  ONC(C[C@H](C(N[C@H](C(N[C@H](C(N)=O)C)=O)CC1=CC2=C(C=C1)C=CC=C2)=O)CC(C)C)=O

• Molecular Formula :

  C24H32N4O5

• Molecular Weight :

  456.53

• Precautions :

  H301

• References & Citations :

  [1]Amit Balakrishnan, et al. Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J Biol Chem. 2006 Jun 16;281 (24) :16691-9.|[2]Shiori Haga, et al. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Res. 2010 Mar;85 (3) :551-5.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [163958-73-4]